Alligator Bioscience Publishes Preclinical Data on Bispecific Antibody ATOR-4066

Strategic Insights -

Alligator Bioscience has announced the publication of a peer-reviewed article in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR). The paper presents preclinical data on ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5 developed using Alligator's proprietary Neo-X-Prime platform and RUBY format. The study highlights the potential of ATOR-4066 to overcome key resistance mechanisms in the tumor microenvironment, demonstrating potent antitumor immunity with localized activation of myeloid cells and T cells within the tumor.

Key Takeaways:

  • Preclinical data on ATOR-4066, a bispecific antibody, were published in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR).
  • ATOR-4066 selectively activates CD40 in human tumor samples, inducing localized activation of myeloid cells and T cells within the tumor, while sparing healthy peripheral tissues.
  • The antibody demonstrated strong anti-tumor activity in tumors with heterogenous CEACAM5 expression, indicating its potential to outperform other tumor targeting therapies.
  • Mechanistic analyses showed that ATOR-4066 efficiently activates the immune system in the tumor, resulting in tumor rejection, and synergistic activity with anti-PD-1 treatment was observed.
  • Søren Bregenholt, CEO of Alligator Bioscience, stated that the publication underscores the potential of the company's Neo-X-Prime platform and RUBY format to generate bispecific antibodies capable of reshaping the tumor microenvironment and driving durable immune responses.

Statistics:

  • 24-month follow-up survival data on mitazalimab, Alligator's lead drug candidate, presented unprecedented survival results in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.
  • The data from the study demonstrated that ATOR-4066 induces strong myeloid and T cell-dependent tumor immunity and synergizes with PD-1 blockade.

Sources:

  • Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR)
  • American Association for Cancer Research (AACR)
  • Alligator Bioscience
  • Nasdaq Stockholm
  • ACCESS Newswire